NDAINJECTIONINJECTABLE
Approved
Apr 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
CORTROSYN (cosyntropin) by R-Pharm US is 12. Approved for infantile spasm, postdural puncture headache. First approved in 1970.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORTROSYN (cosyntropin) is a synthetic adrenocorticotropic hormone (ACTH) that stimulates the adrenal cortex to produce corticosteroids. It is indicated for infantile spasm and postdural puncture headache, working through ACTH receptor binding to trigger corticosteroid production. The 1-24 amino acid sequence provides full biologic activity with minimal immunogenicity compared to natural ACTH.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating team contraction and shift toward lifecycle management rather than growth initiatives.
Mechanism of Action
12.1 Mechanism of Action Cosyntropin exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N-terminal portion of the molecule and that the 1-20 amino acid residue is the minimal sequence retaining full activity.…
Pharmacologic Class:
Adrenocorticotropic Hormone
Worked on CORTROSYN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.